Working... Menu

Acetaminophen Biomarkers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01005173
Recruitment Status : Enrolling by invitation
First Posted : October 30, 2009
Last Update Posted : November 24, 2017
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Arkansas Children's Hospital Research Institute

Brief Summary:
This study is a non-intervention, multicenter study to address biomarkers of acetaminophen toxicity in children. Specifically, the study will examine acetaminophen (APAP) protein adducts and markers of liver injury in the blood samples of hospitalized children and adolescents who are receiving standard doses of acetaminophen, and children and adolescents who are status post acetaminophen overdose. Ultimately, the data generated from this study will be used to establish second generation biomarkers of acetaminophen toxicity, based on specific adduct proteins, which can be used in future risk assessment studies of children receiving acetaminophen.

Condition or disease
Acetaminophen Toxicity

Layout table for study information
Study Type : Observational
Estimated Enrollment : 253 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Identification of New Mechanistic Biomarkers of Adverse Response to Acetaminophen
Study Start Date : August 2009
Estimated Primary Completion Date : June 2018

Resource links provided by the National Library of Medicine

Group A
Subjects receiving recommended doses of acetaminophen in the hospital. 140 Subjects
Group B
Healthy Volunteers - No acetaminophen exposure within 14 days of enrollment 23 Subjects
Group C
Acetaminophen Overdose Subjects - Hospitalized 90 Subjects

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Year to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Children Ages 1-18

Group A - Hospitalized receiving acetaminophen

Group B - Healthy volunteers - no acetaminophen within 14 days

Group C - Acetaminophen Overdose - Hospitalized


Inclusion Criteria:

Group A:

  • Children ages 1-18 inclusive
  • Hospitalized children who are likely to receive or are receiving recommended doses of APAP

Group B:

  • Children ages 1-18 inclusive
  • Children with no APAP use in the past 14 days

Group C:

  • Children ages 1-18 inclusive
  • Hospitalized from an acute overdose of APAP
  • Time of APAP overdose is known or can be estimated within a two hour window

Exclusion Criteria:

Group A:

  • Acute or chronic APAP overdose within 14 days
  • Known history of liver disease or dysfunction

Group B:

  • APAP within the last 14 days
  • Known history of liver disease or dysfunction

Group C:

  • Chronic overdoses of APAP, defined as multiple time point ingestions of APAP
  • History of previous APAP overdose
  • Known pre-existing liver disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01005173

Layout table for location information
United States, Arkansas
Arkansas Children's Hospital
Little Rock, Arkansas, United States, 72202
United States, District of Columbia
Children's National Medical Center
Washington, District of Columbia, United States, 20010
United States, Kentucky
Kosair Charities Pediatric Clinical Research Unit University of Louisville
Louisville, Kentucky, United States, 40202
United States, Missouri
Children's Mercy Hospitals and Clinics
Kansas City, Missouri, United States, 64108
United States, Ohio
Akron Children's Research Center
Akron, Ohio, United States, 44308
University of Toledo Health Science Center
Toledo, Ohio, United States
United States, Texas
Cook's Children's Health System
Fort Worth, Texas, United States, 76104
Baylor College of Medicine - Texas Children's Hospital
Houston, Texas, United States, 77030
Sponsors and Collaborators
Arkansas Children's Hospital Research Institute
National Institutes of Health (NIH)
Layout table for investigator information
Principal Investigator: Laura P James, MD Arkansas Children's Hospital Research Institute

Layout table for additonal information
Responsible Party: Arkansas Children's Hospital Research Institute Identifier: NCT01005173     History of Changes
Other Study ID Numbers: 1R01DK081406-01A1 ( U.S. NIH Grant/Contract )
1 R01 DK081406-01A1 - NIH
First Posted: October 30, 2009    Key Record Dates
Last Update Posted: November 24, 2017
Last Verified: November 2017

Keywords provided by Arkansas Children's Hospital Research Institute:

Additional relevant MeSH terms:
Layout table for MeSH terms
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs